Dana-Farber Cancer Institute: Esophageal Neoplasms trials

The registry lists 11 Esophageal Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Resilience and Equity in Aging, Cancer, and Health (REACH)RecruitingNCT04674267Not applicable
• Serial MRI Scans During Radiation TherapyRecruitingNCT04188535Not applicable
• Pembrolizumab in Refractory Advanced Esophageal CancerCompletedNCT02971956Phase 2Results posted
• FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal CancerCompletedNCT01243619Not applicableResults posted
• CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerCompletedNCT01191697Phase 2Results posted
• Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric CancerCompletedNCT00130689Phase 2Results posted
• MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal CancerWithdrawnNCT02689401Phase 1
• NIR-Guided Sentinel Lymph-Node Mapping for Esophageal CancerCompletedNCT01808417Phase 1
• Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal CancerCompletedNCT00165490Phase 2
• Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric CancerCompletedNCT00165464Phase 2
• Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal CancerCompletedNCT00137852Phase 2